Alzheimer’s disease (AD) often occurs in three stages: mild, moderate, and severe. The symptoms tend to be cumulative and worsen over time.
In addition to memory loss, early clinical symptoms will likely include:
- confusion about the location of familiar places
- taking longer to accomplish normal daily tasks
- trouble handling money and paying bills
- poor judgment leading to bad decisions
- loss of spontaneity and sense of initiative
- mood and personality changes and increased anxiety
As the disease spreads to more regions of the brain, additional clinical symptoms may include:
- increasing memory loss and confusion
- shortened attention span
- problems recognizing friends and family members
- difficulty with language and problems with reading, writing, or working with numbers
- difficulty organizing thoughts and thinking logically
- inability to learn new tasks or to cope with new or unexpected situations
- inappropriate outbursts of anger
- perceptual-motor problems, such as trouble getting out of a chair or setting the table
- repetitive statements or movement, and occasional muscle twitches
- hallucinations, delusions, suspiciousness or paranoia, and irritability
- loss of impulse control, such as undressing at inappropriate times or places or using vulgar language
- exacerbation of behavioral symptoms, such as restlessness, agitation, anxiety, tearfulness, and wandering —especially in the late afternoon or evening—called, “sundowning”
At this point, plaques and tangles, the hallmarks of AD, show in the brain when viewed by the imaging technology MRI. This is the final stage of AD. These symptoms include:
- inability to recognize family and loved ones
- sense of self seems to vanish
- unable to communicate in any way
- lack of bladder and bowel control
- weight loss
- skin infections
- groaning, moaning, or grunting
- increased sleeping
- total dependence on others for their care
- difficulty swallowing (see more on this below)
Conditions With Similar Symptoms
There are other causes of dementia that have similar symptoms to AD. The following list contains the most common ones:
- Parkinson’s disease with dementia. This brain disorder leads to shaking and difficulty with walking, movement, and coordination.
- vascular dementia. It occurs from impaired blood flow to the brain and leads to problems with reasoning, planning, judgment, and memory.
- frontotemporal lobar degeneration. This affects the frontal and temporal lobes of the brain, which are associated with personality, behavior and language.
- frontotemporal dementia. The affects the temporal and frontal lobes that influence decision-making, behavioral control, emotion, and language.
- Pick’s disease. A rare and permanent form of dementia similar to AD except it often affects only certain brain areas.
- supranuclear palsy. a rare brain disorder that causes serious and progressive problems with control of gait and balance, complex eye movement, and thinking problems.
- corticobasal degeneration. This occurs when areas of your brain shrink and nerve cells die over time. The result is growing difficulty moving on one or both sides of your body.
Other Possible Causes of Dementia
- medication side effects
- vitamin B12 deficiency
- chronic alcoholism
- certain tumors or infections of the brain
- blood clots pressing on the brain
- metabolic imbalances, including thyroid, kidney and liver disorders
- Albert, M. S., Dekosky, S. T.,
Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The
diagnosis of mild cognitive impairment due to Alzheimer's disease:
Recommendations from the National Institute on Aging and Alzheimer's
Association workgroup. Alzheimers Dement.
- Alzheimer's Association. (2011). Press Release: New Criteria
and Guidelines for the Diagnosis of Alzheimer's Disease Published for the first
Time in 27 Years. The Alzheimer's
- Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A.,
& Bennett, D. A. (2004). Diabetes mellitus and risk of Alzheimer disease
and decline in cognitive function. Arch
Neurol, 61(5), 661-666.
- Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland,
D., & Jones, E. (2011). Alzheimer's disease. Lancet, 377(9770), 1019-1031.
- Bird, T. D. (2010). Early-Onset Familial Alzheimer Disease. University of Washington, Gene Review.
- Birks, J., & Grimley Evans, J. (2009). Ginkgo biloba for
cognitive impairment and dementia. Cochrane
Database Syst Rev(1), CD003120.
- Bosco, D., Fava, A., Plastino, M., Montalcini, T., &
Pujia, A. (2011). Possible implications of Insulin Resistance and Glucose
metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med.
- Boyle, P. A., Buchman, A. S., Barnes, L. L., & Bennett,
D. A. (2010). Effect of a purpose in life on risk of incident Alzheimer disease
and mild cognitive impairment in community-dwelling older persons. Arch Gen Psychiatry, 67(3), 304-310.
- Boyle, P. A., Buchman, A. S., Barnes, L. L., James, B. D.,
& Bennett, D. A. (2010). Association between life space and risk of
mortality in advanced age. J Am Geriatr
Soc, 58(10), 1925-1930.
- Brinkley, T. E., Lovato, J. F., Arnold, A. M., Furberg, C.
D., Kuller, L. H., Burke, G. L., et al. (2010). Effect of Ginkgo biloba on
blood pressure and incidence of hypertension in elderly men and women. Am J Hypertens, 23(5), 528-533.
- Daviglus, M. L., Bell, C. C., Berrettini, W., Bowen, P. E.,
Connolly, E. S., Cox, N. J., et al. (2010). NIH State-of-the-Science Conference
Statement: Preventing Alzheimer's Disease and Cognitive Decline. NIH Consens State Sci Statements, 27(4).
- De Felice, F. G., Vieira, M. N., Bomfim, T. R., Decker, H.,
Velasco, P. T., Lambert, M. P., et al. (2009). Protection of synapses against
Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of
Abeta oligomers. Proc Natl Acad Sci U S
A, 106(6), 1971-1976.
- deIpolyi, A. R., Rankin, K. P., Mucke, L., Miller, B. L.,
& Gorno-Tempini, M. L. (2007). Spatial cognition and the human navigation
network in AD and MCI. Neurology, 69(10),
- DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L.,
Kronmal, R. A., Ives, D. G., Saxton, J. A., et al. (2008). Ginkgo biloba for
prevention of dementia: a randomized controlled trial. JAMA, 300(19), 2253-2262.
- Fillit, H. M., Butler, R. N., O'Connell, A. W., Albert, M.
S., Birren, J. E., Cotman, C. W., et al. (2002). Achieving and maintaining
cognitive vitality with aging. Mayo Clin
Proc, 77(7), 681-696.
- Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish,
A., Hamshere, M. L., et al. (2009). Genome-wide association study identifies
variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet, 41(10), 1088-1093.
- Herrmann, W., & Obeid, R. (2011). Homocysteine: a
biomarker in neurodegenerative diseases. Clin
Chem Lab Med, 49(3), 435-441.
- Keating, D. J., Chen, C., & Pritchard, M. A. (2006).
Alzheimer's disease and endocytic dysfunction: clues from the Down
syndrome-related proteins, DSCR1 and ITSN1. Ageing
Res Rev, 5(4), 388-401.
- Ladika, D. J., & Gurevitz, S. L. (2011). Identifying the
most common causes of reversible dementias: a review. JAAPA, 24(3), 28-31, 57.
- Li, K., Dai, D., Zhao, B., Yao, L., Yao, S., Wang, B., et al.
(2010). Association between the RAGE G82S polymorphism and Alzheimer's disease.
J Neural Transm, 117(1), 97-104.
- McKhanna, G. M., Knopmanc, D. S., Chertkowd, H., Hyman, B.
T., Clifford R. Jack, J., Kawash, C. H., et al. (2011). The diagnosis of
dementia due to Alzheimer’s disease: Recommendations from the National
Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s & Dementia, 1–7.
- Nation, D. A., Hong, S., Jak, A. J., Delano-Wood, L., Mills,
P. J., Bondi, M. W., et al. (2011). Stress, exercise, and Alzheimer's disease:
A neurovascular pathway. Med Hypotheses.
- National Library of Medicine. (2011). Alzheimer's Disease. Medline Plus; U.S. National Library of
Medicine; National Institutes of Health.
- NCCAM. (2011). National Center for Complementary and
Alternative Medicine: The Ginkgo Evaluation of Memory (GEM) Study. National Institutes of Health' National
Center for Complementary and Alternative Medicine.
- NIA. (2008). Alzheimer's Disease: Unraveling the Mystery. National Institute on Aging; National Institutes of Heath; US
Department of Health and Human Services; NIH Publication Number 08-3782, 1-43.
- NIA. (2011). Caring for a Person with Alzheimer's Disease;
Medicine Chart. National Institutes of
Health; National Institute on Aging; Alzheimer's Disease Education &
- NINDS. (2010). NINDS Alzheimer's Disease Information Page. National Institute of Neurological Disorders
and Stroke; National Institutes of Health; US Department of Health & Human
- NINDS. (2011). Dementia: Hope Through Research. National Institute of Neurological Disorders
and Stroke of the National Institutes of Health.
- Panza, F., Frisardi, V., Imbimbo, B. P., D'Onofrio, G.,
Pietrarossa, G., Seripa, D., et al. (2010). Bapineuzumab: anti-beta-amyloid
monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy, 2(6), 767-782.
- Redish, A. D. (2001). The hippocampal debate: are we asking
the right questions? Behav Brain Res, 127(1-2),
- Reitz, C., Brayne, C., & Mayeux, R. (2011). Epidemiology
of Alzheimer disease. Nat Rev Neurol, 7(3),
- Reitz, C., den Heijer, T., van Duijn, C., Hofman, A., &
Breteler, M. M. (2007). Relation between smoking and risk of dementia and
Alzheimer disease: the Rotterdam Study. Neurology,
- Seneff, S., Wainwright, G., & Mascitelli, L. (2011).
Nutrition and Alzheimer's disease: The detrimental role of a high carbohydrate
diet. Eur J Intern Med, 22(2),
- Snitz, B. E., O'Meara, E. S., Carlson, M. C., Arnold, A. M.,
Ives, D. G., Rapp, S. R., et al. (2009). Ginkgo biloba for preventing cognitive
decline in older adults: a randomized trial. JAMA, 302(24), 2663-2670.
- Solomon, P. R., Adams, F., Silver, A., Zimmer, J., &
DeVeaux, R. (2002). Ginkgo for memory enhancement: a randomized controlled
trial. JAMA, 288(7), 835-840.
- Traykov, L., Rigaud, A. S., Cesaro, P., & Boller, F.
(2007). [Neuropsychological impairment in the early Alzheimer's disease]. Encephale, 33(3 Pt 1), 310-316.
- Uc, E. Y., Rizzo, M., Anderson, S. W., Shi, Q., & Dawson,
J. D. (2004). Driver route-following and safety errors in early Alzheimer
disease. Neurology, 63(5), 832-837.
- Wegiel, J., Gong, C. X., & Hwang, Y. W. (2011). The role
of DYRK1A in neurodegenerative diseases. FEBS
J, 278(2), 236-245.
- Wilson, R. S., Mendes De Leon, C. F., Barnes, L. L.,
Schneider, J. A., Bienias, J. L., Evans, D. A., et al. (2002). Participation in
cognitively stimulating activities and risk of incident Alzheimer disease. JAMA, 287(6), 742-748.
- Yu, F. (2011). Guiding Research and Practice: A Conceptual
Model for Aerobic Exercise Training in Alzheimer's Disease. Am J Alzheimers Dis Other Demen.